荷兰痛风患者对缓解期继续或停用降尿酸治疗的看法:一项混合方法研究
该混合方法研究通过半结构化访谈识别影响痛风患者缓解期继续或停用降尿酸治疗(ULT)的因素,并用最大差异量表评估其相对重要性。访谈18例患者得出10个主题下22个条目;量表研究纳入156例患者,显示感知的关节损伤和痛风发作风险及ULT使用带来保障感最为重要,费用、获取便利性和实际使用最不重要。结果可辅助医患共享决策。
要点
- 感知的关节损伤和痛风发作风险是影响缓解期继续或停用ULT的最重要因素。
- ULT使用带来保障感也是最重要的条目之一。
- 费用、获取ULT的便利性和实际使用是相对最不重要的条目。
核心结论
- 这些结果可辅助共享决策,并为与考虑停用ULT的缓解期痛风患者讨论哪些内容重要提供输入。
- 重点应放在痛风发作和关节损伤的风险上,而不是太侧重于促进获取药物的便利性。
研究设计与样本
- 采用混合方法设计,包括半结构化访谈(子研究1)和最大差异量表研究(子研究2)。
- 子研究1纳入18例患者,子研究2纳入156例患者。
主要发现
- 子研究1通过归纳主题分析识别出10个 overarching 主题下的22个条目。
- 子研究2显示,感知的关节损伤和痛风发作风险以及ULT使用带来一些保障感是最重要的条目。
- 费用、获取ULT的便利性及其实际使用是最不重要的条目。
关键数值与推荐
- 子研究2使用重标概率分数确定条目的相对重要性。
- 原文未报告具体重标概率分数数值。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Long-term gout management is based on reducing serum urate by using urate-lowering therapy (ULT). A lifelong treat-to-target approach is advocated, although a ULT (taper to) stop attempt can be considered (treat-to-avoid symptoms approach) during remission. Exploring the beliefs of patients with gout on long-term ULT strategies during remission is important for optimizing gout management. We aimed to identify factors that influence the decision for continuation or discontinuation of ULT and to determine their relative importance according to patients with gout in remission. METHODS: A mixed-methods design was used. First, semistructured interviews (substudy 1) were conducted to identify barriers and facilitators for the (dis)continuation of ULT using inductive thematic analysis. Afterwards, these barriers/facilitators were summarized into neutrally phrased items and used in a maximum difference scaling study (substudy 2) to determine their relative importance using the rescaled probability score. RESULTS: Substudies 1 and 2 included 18 and 156 patients, respectively. Substudy 1 yielded 22 items within 10 overarching themes. Substudy 2 revealed that the perceived risk of joint damage and gout flares and that ULT use gives some assurance were the most important items. The costs, ease of receiving ULT, and its practical use were the least important items. CONCLUSION: These results can aid shared decision-making and provide input for what is important to discuss with patients with gout in remission when they consider ULT discontinuation. The emphasis should be on the risk of having gout flares and joint damage, not so much on facilitating how easily medication is received.
引用
- Peeters IR, Veenstra F, Wanten SAC, et al. Perspective of Dutch Patients with Gout on Continuation or Discontinuation of Urate-Lowering Therapy During Remission: A Mixed-Methods Study. Arthritis Care Res (Hoboken). 2024. PMID: 38924379. doi:10.1002/acr.25392
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。